Background {#sec1}
==========

Melatonin secreted by the pineal gland during the dark phase of the sleep/wake cycle, is a kind of hormone which periodically regulates several physiological functions \[[@B1]\], including glucose homeostasis \[[@B2]\] and insulin secretion \[[@B3]\]. When the melatonin secretion or the corresponding Melatonin Receptor (MTNR) is abnormal, the metabolism in humans may be seriously damaged \[[@B4]\]. And MTNR exists in ovarian granulosa cells membranes \[[@B5],[@B6]\], therefore, melatonin as a pleiotropic molecule has a direct effect on ovarian function \[[@B7],[@B8]\]. Low melatonin levels in follicular fluid affect the quality and number of oocytes, and ultimately affect the outcome of *in vitro* fertilization (IVF) \[[@B9]\]. Moreover, melatonin treatment can also be used as a combination therapy to help control the blood glucose level \[[@B2]\], slow the progress or improve type 2 diabetes mellitus (T2DM) \[[@B10]\], increase pregnancy rates and improve endocrine levels eventually \[[@B11]\].

Additionally, multiple studies reveal that melatonin secretion is increased in polycystic ovarian syndrome (PCOS) patients \[[@B12]\]. PCOS is a kind of common metabolic and endocrine disorder in reproductive women \[[@B15]\], of which global prevalence is approximately 6--10% \[[@B16],[@B17]\]. It has a variety of heterogeneous clinical manifestations, and approximately 20--30% of patients with PCOS suffer from various complications \[[@B18]\], like metabolic syndrome \[[@B19]\] and insulin resistance (IR) \[[@B20]\], which makes PCOS hard to be explained by a single factor. PCOS is a highly clinical as well as genetic heterogeneity syndrome \[[@B21]\]. For example, oocytes of PCOS patients also have abnormal gene transcription and expression, which will affect individual reproductive capacity \[[@B22]\]. As metabolic disorders have become much more prevalent recently \[[@B23]\], more genome-wide association and cohort studies were conducted and more variant genes and novel single nucleotide polymorphisms (SNPs) are found in large Chinese PCOS population \[[@B24],[@B25]\], which have been confirmed later by multi-ethnic studies \[[@B26],[@B27]\], including thyroid associated protein gene \[[@B28]\], Fat Mass and Obesity (*FTO*) gene \[[@B29],[@B30]\], Follicle-stimulating Hormone Receptor (*FSHR*) gene \[[@B31],[@B32]\], DENN/MADD domain containing 1A gene \[[@B33]\], Vitamin D Receptor (*VDR*) gene \[[@B34]\] and so on.

Additionally, the SNPs of MTNR 1A/B gene (MTNR1A/B) are found to have associations with many kinds of metabolic disorders. For example, MTNR1B rs10830963 polymorphism is not only associated with fasting blood glucose levels, but also with IR and T2DM risk \[[@B37]\]. And MTNR1A rs2119882 is also associated with gestational diabetes mellitus and IR \[[@B38]\]. However, whether MTNR polymorphisms relate to another metabolic disorder, PCOS, is still inconclusive because previous genetic research has shown conflicting conclusions \[[@B39]\]. So, the object of our meta-analysis is to ascertain the association between MTNR1A/B polymorphisms and PCOS.

Methods {#sec2}
=======

Our study was conducted with the requirements of Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) \[[@B40]\]. All data were available from currently published studies, so no informed consent and Ethics Committee approval were required.

Study protocol {#sec2-1}
--------------

Five English databases (PubMed, Embase, Ovid, the Cochrane Library and Web of Science) and three Chinese databases (VIP, CNKI and Wanfang) were searched in our study. And we used three subject heading terms, 'Polycystic ovarian syndrome', 'melatonin' and 'melatonin receptor', as well as the synonyms of these terms confirmed by Medical Subject Headings (MeSH) referred to in the Supplementary Material S1 (Search strategies) \[[@B41]\], where other free words were registered. The latest search results were updated on 14 February 2020. And there were no language restrictions in these search strategies. Finally, all references were exported to EndNote X9 software for further research.

Definitions and results {#sec2-2}
-----------------------

As the definition of PCOS used in the present study, all the eligible studies adopted the 2003 Rotterdam diagnostic inclusion criteria of PCOS \[[@B42]\]: (1) thin ovulation or anovulation. (2) Clinical manifestations of hyperandrogen or hyperandrogenemia. (3) Polycystic ovarian changes, that is, ≥12 follicles with a diameter of 2--9 millimeters on ovary, or ovarian volume \> 10 ml. As long as two of the above criteria are met and other diseases are excluded, PCOS can be diagnosed. The results were the genotype distribution in MTNR gene and the odds ratio (OR) of PCOS.

Eligibility criteria {#sec2-3}
--------------------

Included references needed to meet the following criteria: Assess the association between SNP in MTNR and PCOS risk,Contain particular data, such as the frequency of MTNR genotypes.

Excluded studies should meet the following criteria: Abstracts and reviews,Repeated dissertation,No research on genotype distribution,Non-human research.

Among them, Newcastle--Ottawa Scale (NOS), available from URL (<http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm>) \[[@B43]\], was performed to evaluate the quality of all included studies.

Study selection {#sec2-4}
---------------

All studies retrieved from all the databases were assessed and reviewed by the first and second authors (Shiqi Yi and Hao Shi) based on eligibility criteria. The data extraction results were agreed upon discussion with another first author (Jiawei Xu). Study and descriptors such as author, publication time, country, ethnicity, study period, study type, NOS scores, the number of participants and methods of study were extracted and recorded from the included studies.

The third and fourth authors (Wenbo Li and Qian Li) independently assessed the quality of eligible studies using NOS which consisted of three parts, namely selection, comparability and exposure, and their corresponding eight scoring items. Except for comparability which could score up to two stars, each item could only score up to one star. Possible maximum number of stars in each study was 9. When the score of eligible study in NOS was ≥7, the present study was regarded as high-quality research \[[@B44]\]. When scoring divergences occurred, the sixth investigator (Ying-pu Sun) was consulted.

Statistical analysis {#sec2-5}
--------------------

Review Manager 5.3 software (available from the Cochrane Community, <https://community.cochrane.org/help/tools-and-software/revman-5>) was performed for data analysis \[[@B45]\]. Each study was evaluated by the Hardy--Weinberg equilibrium (H--W equilibrium, HWE) with a chi-square test (χ^2^ test) by IBM SPSS statistics 25 software \[[@B46]\]. Odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were utilized to test the association between each SNPs, rs2119882 and rs10830963 of MTNR1A/B and PCOS with six genetic models used to test the influence of genotype, that is, for rs10830963 (C\> G): allelic (G vs. C), codominant (homozygote (GG vs. CC) and heterozygote (GC vs. CC) models), dominant (GG + GC vs. CC), recessive (GG vs. GC + CC) and superdominant (GG + CC vs. GC) models were calculated; and for rs2119882 (T\> C): allelic (C vs. T), codominant (homozygote (CC vs. TT) and heterozygote (CT vs. TT) models), dominant (CC + CT vs. TT), recessive (CC vs. CT + TT) and superdominant (CC + TT vs. CT) models were calculated \[[@B47],[@B48]\]. Our study used Cochrane Q-test for heterogeneity testing and the *I^2^*, a test statistic, for quantification \[[@B49]\]. In the Q-test, when *P*≥0.1 or *I^2^* ≤ 50%, the fixed-effects model could be established to analyze. Otherwise, the random-effects model could be used. Next, a Z-test was performed to evaluate the statistical significance of combined ORs in quantitative synthesis. And all analysis will use 0.05 as significantly statistical level. Finally, by eliminating the heterogeneous merger studies one by one, the effect of a single heterogeneous study on the entire model was further discussed through a sensitivity analysis. And Stata MP 16.0 software was used to analyze the publication bias by Egger's and Begg's tests.

Results {#sec3}
=======

Study selection {#sec3-1}
---------------

In total, 1028 references were identified after searching from databases (refer to Supplementary Material S1, Search strategies) and their recommended links. Then, all searched reference lists were imported into EndNote X9, which helps to remove duplicate studies. The majority of articles were excluded for unrelated titles and abstracts and other eight articles were excluded because of which studied populations were not PCOS patients, genotype data were not valid, or references were unrelated. Additionally, Song et al. (2015) study \[[@B50]\] was removed because it was a family-based transmission disequilibrium test without control group. Finally, five articles met the quality requirements of meta-analysis and the flow diagram of our study selection is shown in [Figure 1](#F1){ref-type="fig"}.

![Flow diagram of selection process on genetic studies of MTNR polymorphisms with PCOS](bsr-40-bsr20200824-g1){#F1}

Study characteristics {#sec3-2}
---------------------

The eligible references in the present study involved two genes and six polymorphisms, MTNR1B gene (rs10830963, rs10830962, rs4753426, rs1562444, rs12792653) and MTNR1A (rs2119882). Four references, including Xu et al. (2019) \[[@B51]\], Yang et al. (2016) \[[@B52]\], Li et al. (2010) \[[@B53]\] and Wang et al. (2010) \[[@B39]\], reported the associations between rs10830963 and PCOS, including 1145 patients and 1408 controls. And two references, Xu et al. (2019) \[[@B51]\] and Li et al. (2011) \[[@B54]\], reported rs2119882, including 1680 patients and 1472 controls. Other SNPs had not been included in subsequent analysis due to insufficient data. All included studies with an NOS score more than 7, indicated a good level of quality ([Table 1](#T1){ref-type="table"}). The majority populations of the eligible references were Chinese and the methods used to detect gene polymorphisms were polymerase chain reaction (PCR) and sequencing. The studies characteristics are described in [Table 2](#T2){ref-type="table"}. Allele frequencies and genotypes of each study, and the outcome of HWE was listed in [Table 3](#T3){ref-type="table"}.

###### The NOS

  Study                Selection   Comparability   Exposure   Total Score                    
  -------------------- ----------- --------------- ---------- ------------- ---- --- --- --- ---
  Xu et al. (2019)     ★           ★                          ★             ★★   ★   ★   ★   8
  Yang et al. (2016)   ★           ★                          ★             ★★   ★   ★   ★   8
  Song et al.          ★           ★                                        ★★   ★   ★   ★   7
  Li et al. (2011)     ★           ★               ★          ★             ★    ★   ★   ★   8
  Li et al. (2010)     ★           ★               ★          ★             ★    ★   ★   ★   8
  Wang et al. (2010)   ★                           ★          ★             ★★   ★   ★   ★   8

###### Characteristics of the eligible studies in the meta-analysis

  Study         Year      Ethnicity                Patients   MTNR             Study period                    Stydy type      NOS   Case/control   Genotyping methods
  ------------- --------- ------------------------ ---------- ---------------- ------------------------------- --------------- ----- -------------- --------------------
  Xu et al.     01/2019   Chinese                  PCOS       MTNR1A, MTNR1B   March 2013--May 2015            Case--control   8     191+168/215    PCR- sequencing
  Yang et al.   03/2016   Chinese                  PCOS       MTNR1B           January 2012--May 2013          Case--control   8     182/196        PCR- sequencing
  Song et al.   09/2015   Chinese, Han, Shandong   PCOS       MTNR1A, MTNR1B   July 2007--April 2014           Family trios    7     263(789)       PCR- sequencing
  Li et al.     04/2011   Chinese, Han, Shandong   PCOS       MTNR1A           September 2006--February 2008   Case--control   8     481/522        PCR Tm-shift
  Li et al.     10/2010   Chinese, Han, Shandong   PCOS       MTNR1B           February 2005--January 2007     Case--control   8     526/547        PCR Tm-shift
  Wang et al.   11/2010   Chinese                  PCOS       MTNR1B           /                               Case--control   8     364/687        TaqMan-PCR

###### Genotype and allele frequency of rs10830963 and rs2119882 in PCOS patients and controls

  rs10830963           Group     Genotype (*n*)   χ^2^   *P*-value   Allele (*n*)   χ^2^    *P*-value                  
  -------------------- --------- ---------------- ------ ----------- -------------- ------- ----------- ----- -------- -------
  Xu et al. (2019)     PCOS      125              169    65          30.002         0.000   419         299   29.351   0.000
                       Control   114              91     10                                 319         111            
  Yang et al. (2016)   PCOS      50               89     43          6.426          0.040   189         175   5.934    0.015
                       Control   70               98     28                                 238         154            
  Li et al. (2010)     PCOS      143              258    125         15.352         0.000   544         508   13.207   0.000
                       Control   185              281    81                                 651         443            
  Wang et al. (2010)   PCOS      126              185    53          1.201          0.549   437         291   0.746    0.388
                       Control   229              340    118                                798         576            

  **rs2119882**      Group     Genotype (*n*)   χ^2^   *P*-value   Allele (*n*)   χ^2^    *P*-value                  
  ------------------ --------- ---------------- ------ ----------- -------------- ------- ----------- ----- -------- -------
  Xu et al. (2019)   PCOS      68               165    126         16.446         0.000   301         417   17.507   0.000
                     Control   69               97     49                                 235         195            
  Li et al. (2011)   PCOS      167              215    99          9.962          0.007   549         413   9.824    0.002
                     Control   215              236    71                                 666         376            

Quantitative synthesis {#sec3-3}
----------------------

The results of the association between the MTNR polymorphisms and the PCOS risk are shown in [Table 4](#T4){ref-type="table"}. The forest plots of each genetic model are described in [Figures 2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}.

![Forest plots of PCOS risk and the polymorphism of rs10830963 C\>G in MTNR1B\
(**A**) G vs. C in allele. (**B**) GG vs. CC in homozygote. (**C**) GC vs. CC in heterozygote. (**D**) GG+GC vs. CC in dominant. (**E**) GG vs. GC+CC in recessive. (**F**) GG+CC vs. GC in superdominant.](bsr-40-bsr20200824-g2){#F2}

![Forest plots of PCOS risk and the polymorphism of rs2119882 T\>C in MTNR1A\
(**A**) C vs. T in allele. (**B**) CC vs. TT in homozygote. (**C**) CT vs. TT in heterozygote. (**D**) CC+CT vs. TT in dominant. (**E**) CC vs. CT+TT in recessive. (**F**) CC+TT vs. CT in superdominant.](bsr-40-bsr20200824-g3){#F3}

###### Six genetic models of MTNR genes

                   Allele   Homozygote       Heterozygote                                                                             
  ------------ --- -------- ---------------- -------------- ----- ------ ---------------- ------ ----- ------ ---------------- ------ -----
  rs10830963   4   1.38     \[1.00, 1.89\]   0.05           88%   2.05   \[0.99, 4.21\]   0.05   89%   1.21   \[1.03, 1.42\]   0.02   44%
  rs2129882    2   1.44     \[1.25, 1.67\]   0.00           54%   2.07   \[1.55, 2.76\]   0.00   34%   1.32   \[1.05, 1.65\]   0.02   56%

                   Dominant   Recessive        Superdominant                                                                             
  ------------ --- ---------- ---------------- --------------- ----- ------ ---------------- ------ ----- ------ ---------------- ------ ----
  rs10830963   4   1.40       \[1.00, 1.95\]   0.05            78%   1.79   \[0.98, 3.27\]   0.06   87%   0.99   \[0.85, 1.14\]   0.87   0%
  rs2129882    2   1.59       \[1.05, 2.41\]   0.03            69%   1.72   \[1.34, 2.22\]   0.00   0%    1.00   \[0.82, 1.22\]   0.99   0%

### Analysis of rs10830963 polymorphisms in MTNR1B {#sec3-3-1}

To study the relationship between rs10830963 (C\>G) and PCOS risk, we included four case--control studies ([Table 3](#T3){ref-type="table"}) and analyzed them with six genetic models \[[@B55]\] ([Table 4](#T4){ref-type="table"}, [Figure 2](#F2){ref-type="fig"}). Among them, in the heterozygote model, the variation was significantly associated with PCOS occurrence (OR: 1.21, 95% CI: 1.03--1.42, *P*=0.02, *I^2^* = 44%). In the allelic, homozygote and dominant model, the variations were weakly associated to PCOS risk (OR: 1.38, 95% CI: 1.00--1.89, *P*=0.05, *I^2^* = 88%; OR: 2.05, 95% CI: 0.99--4.21, *P*=0.05, *I^2^* = 89%; OR: 1.40, 95% CI: 1.00--1.95, *P*=0.05, *I^2^* = 78%). In the recessive model, this mutation had a weaker association (OR: 1.79, 95% CI: 0.98--3.27, *P*=0.06, *I^2^* = 87%). And in last model, the superdominant model, no statistically significant association were found (OR: 0.99, 95% CI: 0.85--1.14, *P*=0.87, *I^2^* = 0%). All studies were evenly distributed on both sides of the center line, and no obvious publication bias was found.

### rs2119882 polymorphisms analysis in MTNR1A {#sec3-3-2}

To study the association between rs2119882 and PCOS risk, we included two case--control studies ([Table 3](#T3){ref-type="table"}) and used six genetic models for analysis ([Table 4](#T4){ref-type="table"}, [Figure 3](#F3){ref-type="fig"}). In five genetic models, allelic, homozygote, heterozygote, dominant, recessive and superdominant, significant statistical associations were found (OR: 1.44, 95% CI: 1.25--1.67, *P*\<0.001, *I^2^* = 54%; OR: 2.07, 95% CI: 1.55--2.76, *P*\<0.001, *I^2^* = 34%; OR: 1.32, 95% CI: 1.05--1.65, *P*=0.02, *I^2^* = 56%; OR: 1.59, 95% CI: 1.05--2.41, *P*=0.03, *I^2^* = 69%; OR: 1.72, 95% CI: 1.34--2.22, *P*\<0.001, *I^2^* = 0%). However, in the superdominant model, no significant statistical association was found (OR: 1.00, 95% CI: 0.82--1.22, *P*=0.99, *I^2^* = 0%). All models had low or moderate heterogeneity, so the fixed-effect models were used to analyze them.

Sensitivity analysis {#sec3-4}
--------------------

For genetic models with high heterogeneity (*I^2^* and *P*≤0.01), a sensitivity analysis was conducted by removing all the eligible references one by one in each model to assess the influence of each reference heterogeneity on the whole model analysis \[[@B56]\]. More details in forest plots and funnel plots are shown in [Figure 4](#F4){ref-type="fig"} and [Table 5](#T5){ref-type="table"}. After excluding the study of Wang et al. (2010) \[[@B39]\], the allelic, homozygote, dominant and recessive models in rs10830963 had significant statistical correlation with PCOS risk (OR: 1.58, 95% CI: 1.23--2.02, *P*=0.000, *I^2^* = 70%; OR: 2.78, 95% CI: 1.51--5.10, *P*=0.001, *I^2^* = 73%; OR: 1.58, 95% CI: 1.31--1.90, *P*=0.000, *I^2^* = 50%; OR: 2.30, 95% CI: 1.40--3.77, *P*=0.001, *I^2^* = 67%).

![Forest plots and funnel plots of rs10830963 when Wang et al.'s study was removed\
(**A,E**) G vs. C in allele. (**B,F**) GG vs. CC in homozygote. (**C,G**) GG+GC vs. CC in dominant. (**D,H**) GG vs. GC+CC in recessive.](bsr-40-bsr20200824-g4){#F4}

###### Sensitivity analysis of rs10830963 C\> G

  Model        OR     95% CI           *P*     *I^2^*
  ------------ ------ ---------------- ------- --------
  Allele       1.58   \[1.34, 2.02\]   0.000   70%
  Homozygote   2.78   \[1.51, 5.10\]   0.001   73%
  Dominant     1.58   \[1.31, 1.90\]   0.000   50%
  Recessive    2.30   \[1.40, 3.77\]   0.001   67%

Publication bias {#sec3-5}
----------------

Due to the limited number of available references \[[@B44]\], publication bias was investigated only for the relationship between rs10830963 and PCOS risk by Stata MP 16.0 software. The result of heterozygote model (GC vs. CC) is shown in [Figure 5](#F5){ref-type="fig"}. In Egger's test, *P* was 0.469, while similarly in Begg's test *P* was 0.497. Because both the *P*-values were more than 0.1, so no publication bias was found. Relationship between rs10830963 and PCOS risk was relatively stable and convincing.

![Egger's test and Begg's funnel plot of rs10830963 for heterozygote model\
(**A**) Egger's regression test. (**B**) Begg's funnel plot.](bsr-40-bsr20200824-g5){#F5}

Discussion {#sec4}
==========

As one among common endocrine disorders in gynecological reproduction, the PCOS pathogenesis is still unclear. Family studies revealed aggregation in PCOS \[[@B57]\], but no precise genetic mechanism can explain the etiology. Because these patients have hyperinsulinemia and IR, genes like MTNR1A/B related to insulin secretion possibly play a crucial role in PCOS progression. At the same time, recently several researches have been conducted or been registered \[[@B58]\] to determine the relationship between MTNR genes and PCOS susceptibility. But these researches have shown opposite results, so our study aims to further elaborate the relationship between MTNR1A/B gene and the risk of PCOS.

Melatonin works by activating two important G protein-coupled receptors, MT1 and MT2 \[[@B59]\]. By querying this National Center for Biotechnology Information (NCBI) database, it is known that the *MTNR1A* gene that encodes MT1 is located on the chromosome 4q35.2, and the *MTNR1B* gene of MT2 is located on chromosome 11q14.3. Rs10830963 is located in the intron region between the two exons encoding MTNR1B, while rs2119882 is located in the MTNR1A promoter region. Although these relative positions of SNPs in MTNR are different, the results for all genetic models in this two SNPs are still similar. However, the limitation of our study is that we only discussed from the perspective of MTNR gene while other SNPs are ignored. Because the pathogenesis of PCOS is complex and different genome-wide association studies (GWASs) conclusions are more heterogeneous \[[@B60]\], multiple SNPs mutations may affect metabolic and endocrine profiles in the same PCOS patient, such as insulin receptor gene (INSR) and luteinizing hormone/choriogonadotropin receptor (LHCGR) \[[@B61]\]. Therefore, further research is expected to combining multi-racial GWAS results of arrays by bioinformatics \[[@B62],[@B63]\] and take other gene receptor into consideration to analysis-related molecular pathways \[[@B64]\].

In our meta-analysis, we find that in the heterozygote model, MTNR1B rs10830963 polymorphism is significantly associated with the PCOS occurrence. Through the sensitivity analysis, after excluding Wang et al. study \[[@B39]\], multiple model analyses showed that rs10830963 also has a significant correlation (the allelic, homozygote, dominant and recessive models). This may be due to the large heterogeneity of the present study. First, the study was conducted 10 years ago and its population was not in H--W equilibrium, possibly due to the bias in collecting participants in a limited geographical region. Second, the article does not report the period for recruiting the participants. Therefore, the study cannot rule out the effect of selection bias on the population. Finally, the SNPs are in a strong linkage disequilibrium and there may be a certain association between linkage markers. In addition, due to the large heterogeneity in different ethnicity, our study still needs large sample, multi-center and multi-ethnic studies to confirm.

Moreover, obese women in PCOS patients can be complicated with T2DM \[[@B65]\]. At the same time, their IR level is higher than normal, which can effectively predict impaired glucose tolerance and the occurrence of metabolic syndrome \[[@B66]\]. MTNR is also a candidate gene for IR and gestational diabetes mellitus \[[@B38]\]. So, further studies can take the clinical heterogeneity of PCOS into consideration and divide patients into different groups, such as obese and non-obese groups by body mass index \[[@B67]\], in following subgroup and phenotype analysis of SNPs.

As a result of weak endocrine regulation of melatonin through mutation receptor, to some extent, our meta-analysis supports the feasibility and acceptability of appropriate melatonin supplementation for PCOS \[[@B68],[@B69]\]. At the same time, some studies have suggested that inositol can also be used to an novel and additional treatment of PCOS to improve symptoms \[[@B70]\], because as an insulin sensitizer it can decrease the levels of androgen, improve glucose metabolism \[[@B73]\], and restore spontaneous ovulation \[[@B74],[@B75]\]. But due to the limited study of melatonin and inositol combination therapy \[[@B76],[@B77]\], the clinical outcomes of IVF are still uncertain \[[@B78],[@B79]\]. Therefore, the follow-up systematic review and meta-analysis is recommended to further confirm the combination therapy effect of melatonin and other drugs for PCOS.

Conclusion {#sec5}
==========

The SNPs rs10830963 and rs2119882 of MTNR1B and MTNR1A, are associated with a much higher PCOS risk in Chinese population. And above conclusions still require confirmation by future study including much larger multi-ethnic studies and other SNPs instead of the above conclusions.
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